DocDollars

Vertex Pharmaceuticals Incorporated

MA · United States · Reporting entity ID 100000000184

Total reported 2019–2025
$691.1M
#26 of 2,960 reporting companies — 0.8% of all reported industry payments
$70.0M in general payments across 65,857 records, plus $621.1M in research funding across 7,003 records.

How it breaks down

General payments $69,998,865
Research funding $621,084,483

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Vertex Pharmaceuticals Incorporated reported $691.1M to US doctors and teaching hospitals from 2019 to 2025, ranking #26 of 2,960 reporting companies. 90% of that was research funding and 10% general payments such as consulting, speaking, food and travel. 65,857 general payment records and 7,003 research records were filed.

Common questions about Vertex Pharmaceuticals Incorporated

How much has Vertex Pharmaceuticals Incorporated paid US doctors?

Vertex Pharmaceuticals Incorporated reported $691,083,348 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $69,998,865 in general payments, $621,084,483 in research funding.

How does Vertex Pharmaceuticals Incorporated rank among drug and device companies?

It ranks #26 of 2,960 reporting entities by total reported value, about 0.8% of all industry payments in the dataset.

Does a payment from Vertex Pharmaceuticals Incorporated mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.